Abstract
We describe successful treatment of 3 cases of human herpesvirus 6 (HHV-6) encephalitis/myelitis following cord blood transplantation (CBT). Ganciclovir (GCV) (10 mg/kg/day) reduced HHV-6 load to undetectable levels in cerebrospinal fluid (CSF). Early dose reduction in the presence of HHV-6 detectable in CSF resulted in an increased HHV-6 load. GCV was capably shifted to valganciclovir (VGCV) with an almost equivalent concentration. GCV/VGCV may be effective for HHV-6 encephalitis/myelitis after CBT, although HHV-6 load in CSF should be monitored.
Keywords:
HHV-6; cerebrospinal fluid; cord blood transplantation; encephalitis; ganciclovir; valganciclovir.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
MeSH terms
-
Adult
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / therapeutic use*
-
Child, Preschool
-
DNA, Viral
-
Encephalitis, Viral / cerebrospinal fluid
-
Encephalitis, Viral / drug therapy*
-
Encephalitis, Viral / virology
-
Female
-
Fetal Blood
-
Ganciclovir / administration & dosage
-
Ganciclovir / analogs & derivatives
-
Ganciclovir / therapeutic use
-
Hematopoietic Stem Cell Transplantation / adverse effects*
-
Herpesvirus 6, Human / isolation & purification*
-
Humans
-
Male
-
Myelitis / cerebrospinal fluid
-
Myelitis / drug therapy*
-
Myelitis / virology
-
Myeloablative Agonists / adverse effects
-
Roseolovirus Infections / cerebrospinal fluid
-
Roseolovirus Infections / drug therapy*
-
Roseolovirus Infections / virology
-
Transplantation Conditioning / adverse effects*
-
Treatment Outcome
-
Valganciclovir
-
Viral Load / drug effects*
-
Young Adult
Substances
-
Antiviral Agents
-
DNA, Viral
-
Myeloablative Agonists
-
Valganciclovir
-
Ganciclovir
Supplementary concepts
-
Human Herpesvirus 6 encephalitis